Session Title: Free Paper Session 18: New Drug & Treatment Technology
Session Date/Time: Saturday 09/09/2017 | 14:30-16:00
Paper Time: 15:12
Venue: Room 120
First Author: : Y.Imamura JAPAN
Co Author(s): : A. Suzuki Y. Takano J. Ogawa Y. Ando M. Ishida A. Baba
To examine if oral intake of mineralcorticoid receptor inhibitor, eplerenone, has a dose-dependent effect for serous retinal detachment in patients with chronic central serous chorioretinopathy.
Retrospective, observational study at Kitasato Institute Hospital
The medical records of 25 Japanese patients with chronic CSC with serous retinal detachment who had received oral eplerenone were retrospectively reviewed. The central macular thickness (CMT) and best-corrected visual acuity (BCVA) were measured at baseline, 1 month and 3 months after commencement of oral eplerenone. The dose of eplerenone was determined as 12.5mg, 25mg, or 50mg per day.
The mean age of the 25 patients (5 women) was 59.5±11.1 years (±standard deviation). All of the patients had at least 5 months of visual symptoms in the affected eye. The mean interval between the onset of CSC and the commencement of eplerenone treatment was 47.6 ± 47.7 months with a range of 5 to 180 months. The average CMT at baseline was significantly reduced from 254±110 µm to 189±64 µm at 3 months (P=0.028; unpaired t test). The patients treated with higher doses of eplerenone were more likely to show the increased changes of CMT at 1 month compared with baseline (rs=-0.42, P=0.044, Spearman's rank correlation coefficient) and 3 months (rs=-0.866, P<0.0001)
Oral administration of eplerenone was effective for chronic central serous chorioretinopathy and had a dose-dependent effect.